• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症的疾病进展:结合医生和患者的观点?

Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?

机构信息

Department of Neurology, VU University Medical Center, The Netherlands.

出版信息

Mult Scler. 2011 Feb;17(2):234-40. doi: 10.1177/1352458510385505. Epub 2010 Oct 26.

DOI:10.1177/1352458510385505
PMID:20978037
Abstract

BACKGROUND

To assess disease progression in multiple sclerosis (MS) several outcome measures are available. The interrelation of changes on different scales has not been studied extensively and the concept of combining scales has only recently been introduced in MS.

OBJECTIVE

To explore combining different clinical outcome measures in the evaluation of disease progression in MS.

METHODS

In 553 patients we studied the presence of relevant changes according to standard definitions on the Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW) and the Multiple Sclerosis Impact Scale (MSIS-29). We examined 'exclusive worsening' (worsening on one measure while not worsening on any other measure) and 'opposing changes' (worsening on one measure while improving on another measure). Finally, we investigated the impact of combining assessments.

RESULTS

Based on the EDSS alone, 140 patients progressed. However, almost twice as many (275) showed worsening on any of the clinical outcome measures. Exclusive worsening was observed in 37 patients on the EDSS, 13 on the 9HPT, 39 on the T25FW and 44 on the MSIS physical. Of all worsened patients 76 (28%) showed opposing changes, a phenomenon predominantly observed when combining physician-based and patient-derived outcome measures.

CONCLUSION

When assessing disease progression in MS, sensitivity to change can be increased by combining different outcome measures. The added value is especially present when combining measures from different perspectives. However, further research is needed to evaluate the optimal way to combine outcome measures before implementing this strategy in clinical studies.

摘要

背景

为了评估多发性硬化症 (MS) 的疾病进展,有多种可供选择的评估方法。不同量表上的变化之间的相关性尚未得到广泛研究,并且在 MS 中,组合量表的概念直到最近才被引入。

目的

探讨在 MS 疾病进展评估中结合使用不同的临床评估方法。

方法

我们对 553 名患者进行了研究,根据扩展残疾状态量表 (EDSS)、九孔钉测试 (9HPT)、25 英尺计时步行测试 (T25FW) 和多发性硬化症影响量表 (MSIS-29) 的标准定义,研究了相关变化的存在。我们检查了“单独恶化”(一种评估方法恶化而其他评估方法没有恶化)和“相反变化”(一种评估方法恶化而另一种评估方法改善)。最后,我们还研究了结合评估的影响。

结果

仅根据 EDSS,有 140 名患者进展。然而,几乎两倍(275 名)的患者在任何一种临床评估方法上都出现了恶化。EDSS 上有 37 名患者出现单独恶化,9HPT 上有 13 名,T25FW 上有 39 名,MSIS 身体功能上有 44 名。所有恶化的患者中有 76 名(28%)出现了相反的变化,这种现象主要出现在结合医生和患者评估结果的情况下。

结论

在评估 MS 的疾病进展时,通过结合使用不同的评估方法,可以提高对变化的敏感性。当从不同角度结合评估方法时,这种附加价值更为明显。然而,在将这种策略应用于临床研究之前,还需要进一步研究以评估最佳的组合评估方法。

相似文献

1
Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?多发性硬化症的疾病进展:结合医生和患者的观点?
Mult Scler. 2011 Feb;17(2):234-40. doi: 10.1177/1352458510385505. Epub 2010 Oct 26.
2
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史:一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
3
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.原发进展型与复发缓解型多发性硬化症:脑脊液寡克隆 IgM 的存在及其预后价值。
Mult Scler. 2011 Mar;17(3):303-11. doi: 10.1177/1352458510386996. Epub 2010 Nov 15.
4
The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.使用多发性硬化症特定条件的措施来为卫生政策决策提供信息:从 MSWS-12 到 EQ-5D 的映射。
Mult Scler. 2012 Jun;18(6):853-61. doi: 10.1177/1352458511429319. Epub 2011 Nov 22.
5
Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.下丘脑-垂体-肾上腺轴活动可预测多发性硬化症的疾病进展。
J Neuroimmunol. 2005 Aug;165(1-2):186-91. doi: 10.1016/j.jneuroim.2005.04.014.
6
The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.长期“良性”多发性硬化症的心理社会和认知影响。
Mult Scler. 2011 Nov;17(11):1375-83. doi: 10.1177/1352458511410343. Epub 2011 Jun 15.
7
Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.多发性硬化症不同疾病阶段残疾的决定因素:一项多参数磁共振研究。
Arch Neurol. 2007 Aug;64(8):1163-8. doi: 10.1001/archneur.64.8.1163.
8
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.扩展残疾状态量表(EDSS)和多发性硬化功能综合评分(MSFC)在原发性进行性多发性硬化中的反应性和预测价值。
Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.
9
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.复发缓解型多发性硬化轻度残疾患者的认知障碍及其与疾病指标的关系:多发性硬化认知障碍(COGIMUS)研究的基线结果
Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.
10
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.多发性硬化症中的脑脊液 CXCL13:疾病进程的提示性预后标志物。
Mult Scler. 2011 Mar;17(3):335-43. doi: 10.1177/1352458510389102. Epub 2010 Dec 6.

引用本文的文献

1
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.多发性硬化症的疾病进展:一项探索患者观点的文献综述
Patient Prefer Adherence. 2021 Jan 8;15:15-27. doi: 10.2147/PPA.S268829. eCollection 2021.
2
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.每个故事都有两面性:四位患者和一位医疗保健专业人员对多发性硬化症疾病进展的看法。
Neurol Ther. 2019 Dec;8(2):185-205. doi: 10.1007/s40120-019-0141-4. Epub 2019 Jul 4.
3
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
近几十年来多发性硬化症达到残疾里程碑风险的变化:瑞典一项全国范围内基于人群的队列研究。
JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330.
4
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.阿仑单抗可改善复发缓解型多发性硬化症(MS)活动期患者先前存在的残疾状况。
Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12.
5
Anorectal dysfunction in multiple sclerosis: a systematic review.多发性硬化症中的肛门直肠功能障碍:一项系统综述。
ISRN Neurol. 2012;2012:376023. doi: 10.5402/2012/376023. Epub 2012 Jul 29.